Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Amgen (AMGN – Research Report) and Mind Medicine (MNMD – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Legend Biotech (LEGN)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Legend Biotech on January 8 and set a price target of $66.00. The company’s shares closed last Monday at $23.70.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $67.30 average price target, which is a 184.1% upside from current levels. In a report issued on January 7, Oppenheimer also initiated coverage with a Buy rating on the stock with a $75.00 price target.
See today’s best-performing stocks on TipRanks >>
Amgen (AMGN)
RBC Capital analyst Luca Issi maintained a Buy rating on Amgen on January 8 and set a price target of $335.00. The company’s shares closed last Monday at $325.54.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $345.87, which is a 5.3% upside from current levels. In a report issued on January 7, UBS also upgraded the stock to Buy with a $380.00 price target.
Mind Medicine (MNMD)
Needham analyst Ami Fadia reiterated a Buy rating on Mind Medicine yesterday and set a price target of $28.00. The company’s shares closed last Monday at $13.88.
According to TipRanks.com, Fadia is a 5-star analyst with an average return of
Currently, the analyst consensus on Mind Medicine is a Strong Buy with an average price target of $31.11, a 125.4% upside from current levels. In a report issued on December 31, Chardan Capital also initiated coverage with a Buy rating on the stock with a $20.00 price target.
